Dr. Carlos Fernandez is the founder and Principal Consultant for CRF Consulting Services.


Dr. Fernandez has broad experience in conducting clinical and epidemiological research, and is knowledgeable in the clinical pharmacology and pharmacotherapy of various disease states, in particular central nervous systems disorders. He is skillful in managing multidisciplinary scientific project teams from project creation through to completion and skilled in gathering, analyzing and summarizing scientific information into comprehensive oral and written reports.


Dr. Fernandez is adept in utilizing critical judgement skills in evaluating new technologies, external consultants, and developing new educational programs for various health care professionals. Dr. Fernandez is highly effective in communicating with team members and interfacing with different departments.


Dr. Fernandez’ unique expertise is regularly sought out for research and educational projects and consulting by academic institutions, clinical practice settings, industry, community groups, and as peer reviewer for many well known scientific and medical journals including Neurology, BMC Geriatrics, BMJ, Canadian Medical Association Journal, American Heart Journal, Pharmacoepidemiology and Drug Safety, Annals of Internal Medicine, and others.


Dr. Fernandez has 26 years professional experience including community pharmacy, hospital pharmacy, long-term care, primary care, academia, pharmaceutical industry research and development. His areas of expertise include geriatric pharmacology, epidemiology, neuropsychopharmacology, Alzheimer’s disease and related disorders, mood, anxiety and sleep disorders.


Dr. Fernandez received his undergraduate degree in pharmacy from Dalhousie University in 1990, a PharmD from Wayne State University in 1996 and completed postdoctoral training in the Division of Geriatric Medicine, Dalhousie University, from 1996–98.

Select Publications

  1. Markle-Reid M, Ploeg J, Fisher K, Reimer H, Kaasalainen S, Gafni A, Gruneir A, Kirkconnell R, Marzouk S, Akhtar-Danesh N, Thabane L, Rojas-Fernandez C, Upshur R. The ageing, community and health research unit-Community partnership program for older adults with type 2 diabetes and multiple chronic conditions: A feasibility study. Pilot and Feasibility Studies. 2016;2:24.

  2. Leat SJ, Krishnamoorthy A, Carbonara A, Gold D, Rojas-Fernandez C. Improving the legibility of prescription medication labels for older adults and adults with visual impairment. Can Pharm J (Ott). 2016 May;149(3):174-84.

  3. Rojas-Fernandez CH, Hudani Z, Bittner V. Statins and cognitive side effects: What cardiologists need to know. Endocrinol Metab Clinic North Am 2016 Mar;45(1):101-16.

  4. Boghossian TA, Rashid FJ, Welch V, Rojas-Fernandez C, Moayyedi P, Pottie K, Walsh K, Pizzola L, Thompson W, Farrell B. Deprescribing versus continuation of chronic proton pump inhibitor use in adults (Protocol). Cochrane Database of Systematic Reviews 2015, Issue 11. Art. No.: CD011969. DOI: 10.1002/14651858.CD011969.

  5. Hudani Z, Rojas-Fernandez CH. A scoping review on medication adherence in older patients with cognitive impairment or dementia. Res Social Adm Pharm 2015 Dec 2. pii: S1551-7411(15)00271- 5. doi:10.1016/j.sapharm.2015.11.011

  6. Gibbs JC, McArthur C, Milligan J, Clemson L, Lee L, Boscart VM, Heckman G, Rojas-Fernandez CH, Stolee P, Griangregorio L. Measuring the implementation of a group-based Lifestyle-Integrated Functional Exercise (Mi-Life) intervention delivered in primary care for older adults aged 75 years or older: a pilot feasibility study protocol. Pilot and Feasibility Studies. 2015;1:20. DOI 10.1186/s40814-015.0016- 0.

  7. Rojas-Fernandez CH. Alzheimer’s disease and related disorders: How pharmacists can make an important contribution to patient care. Pharmacy Practice 2015;2:25-32.

  8. Rojas-Fernandez CH, Dadfar F, Wong A, Brown SG. Use of fall risk increasing drugs in residents of retirement villages: A pilot study of long term care and retirement home residents in Ontario, Canada. BMC Res Notes 2015;8:568. DOI 10.1186/s13104-015- 1557-2.

  9. Leat S, Krishnamoorthy A, Carbonara A, Gold D, Rojas-Fernandez CH. The legibility of prescription medication labeling in Canada: Moving from pharmacy centred to patient centred labels. Can Pharm J 2014;147:179-87.

  10. Rojas-Fernandez CH. Can 5-HT 3 antagonists really contribute to serotonin toxicity? A call for clarity and pharmacological law and order. Drugs: Real World Outcomes 2014; 1:3-5.

  11. Rojas-Fernandez CH, Stephenson A, Fischer HD, Wang X, Mestre T, Hutson JR, Pondal M, Lee DS, Rochon P, Marras C. Current use of domperidone and coprescribing of medications that increase its arrhythmogenic potential among older adults: A population-based cohort study in Ontario, Canada. Drugs Ageing 2014 Sep 17. [Epub ahead of print.

  12. Rojas-Fernandez CH, Chen Y. Use of ultra low-dose doxepin for treatment of primary insomnia in older people. Can Pharm J, 2014;147:281-289.

  13. Rojas-Fernandez CH, Patel T, Lee L. An interdisciplinary memory clinic: A novel practice setting for pharmacists in primary care in Ontario, Canada. Ann Pharmacother 2014;48:785-95.

  14. Rojas-Fernandez CH, Seymour N. Helping Pharmacists to Reduce Fall risk in Long-Term Care: Development and Pilot Testing a Clinical Tool to Facilitate the Medication Review Process. Can Pharm J 2014;147:171-178.

  15. Leat S, Ahrens K, Kirshnamoorthy A, Gold D, Rojas-Fernandez CH. The Legibility of Prescription Medication Labeling in Canada-Do Labels Meet Guidelines? Can Pharm J 2014, 147:179-187.

  16. Rojas-Fernandez CH, Mikhail M, Brown SG. Psychotropic and cognitive enhancing medication use and its documentation in contemporary long term care practice. Ann Pharmacother 2014;48:438-46.

  17. Rojas-Fernandez CH. Little evidence that cholinesterase inhibitors prevent progression of mild cognitive impairment to dementia, but they are associated with adverse effects. Evid Based Ment Health 2013 Jan 7. PMID 23299054 [invited commentary].

  18. Rojas-Fernandez CH, Mikhail M. Contemporary concepts in the pharmacotherapy of depression in older people. Can Pharm J 2012;145:128-135.

  19. Rojas-Fernandez CH, Cameron J. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012;46:696-702.

  20. Rojas-Fernandez CH, MacLaughlin EJ, Dore NL, Ebsary S. Assessing the potential adverse consequences of supplemental calcium on cardiovascular outcomes: Should we change our approach to bone health? Ann Pharmacother 2012; 46:549-57.

  21. Rojas-Fernandez CH, Miller LJ, Sadowski CA. Considerations in the treatment of Geriatric Depression: Overview of pharmacotherapeutic and psychotherapeutic treatment options. Research in Gerontological Nursing 2010; 3(3):176-186.

  22. Rojas-Fernandez CH, Moorhouse P. Current concepts in vascular cognitive impairment and pharmacotherapeutic implications. Ann Pharmacother 2009:43(7):1310-23.

  23. Xu KT, Rojas-Fernandez CH. Ancillary community pharmacy services provided to older people in a largely rural and ethnically diverse region: A survey of consumers in West Texas. Journal of Rural Health 2003;19:79-86.

  24. Rojas-Fernandez CH, Eng M, Allie ND. Pharmacological management of behavioral and psychological symptoms of dementia in nursing home residents by clinical pharmacists: Results from a pilot study. Pharmacotherapy 2003;23:217-21.

  25. Rojas-Fernandez CH, Chen M, Fernandez HL. Implications of amyloid precursor protein and subsequent -amyloid production to the pharmacotherapy of Alzheimer’s disease. Pharmacotherapy 2002;22:1547-63.

  26. Rojas-Fernandez CH, Lapane KL, MacKnight C, Howard K. Undertreatment of osteoporosis in residents of nursing homes: Population-based study with use of the Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. Endocr Pract 2002; 8:335-42.

  27. Sleeper RB, Rojas-Fernandez C. Underutilisation of aspirin for secondary prophylaxis of cardiovascular disease in a long term care facility. Am J Health Syst Pharm 2002;59:1294-5.

  28. Luan W, Raehl C, Rojas-Fernandez C. Consensus for diabetes mellitus management in geriatric nursing home residents. Consult Pharm 2002;17:37-43.

  29. Rojas-Fernandez C, Lanctôt KL, Allen D, MacKnight C. Pharmacotherapy of behavioral and psychological symptoms of dementia: Time for a different paradigm? Pharmacotherapy 2001;21(1):74-102.

  30. Sleeper R, Bond CA, Rojas-Fernandez C. Psychotropic Medications and Falls: New Evidence Pertaining to Serotonin Reuptake Inhibitors. Pharmacotherapy 2000; 20(3):307-17.

  31. Rojas-Fernandez C, MacKnight C. Dementia with Lewy Bodies: Review and pharmacotherapeutic implications. Pharmacotherapy 1999;19(7):795-803.

  32. Rojas-Fernandez C, Thomas V, Carver D, Tonks RS. Suboptimal use of antidepressants in the elderly: A population-based study in Nova Scotia. Clinical Therapeutics 1999;21(11):1937-50.

  33. Rojas-Fernandez C, G. Kephart, I. Sketris.Acetylsalicylic acid (ASA) use in Nova Scotians with myocardial infarction or stroke: data from a population-based study. Can J Cardiol 1999;15(3):291-6.

  34. Rojas-Fernandez C, Carver D., Tonks RS. Population trends in the prevalence of benzodiazepine use in the older population of Nova Scotia: A cause for concern? Can J Clin Pharmacol 1999;6(3):149-156.

Find all publications by Dr. Fernandez at:


We'd love to hear from you